Financial Comparison: Corbus Pharmaceuticals (CRBP) vs. Impax Laboratories (IPXL)

Corbus Pharmaceuticals (NASDAQ:CRBP) and Impax Laboratories (NASDAQ:IPXL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Valuation and Earnings

This table compares Corbus Pharmaceuticals and Impax Laboratories’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corbus Pharmaceuticals $2.44 million 169.99 -$32.42 million ($0.65) -11.15
Impax Laboratories $775.79 million 1.74 -$469.28 million $0.63 29.05

Corbus Pharmaceuticals has higher earnings, but lower revenue than Impax Laboratories. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Impax Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

42.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 90.4% of Impax Laboratories shares are held by institutional investors. 11.9% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 3.2% of Impax Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Corbus Pharmaceuticals has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Impax Laboratories has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.

Profitability

This table compares Corbus Pharmaceuticals and Impax Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corbus Pharmaceuticals N/A -78.61% -65.55%
Impax Laboratories -60.49% 10.42% 2.83%

Analyst Ratings

This is a breakdown of recent ratings for Corbus Pharmaceuticals and Impax Laboratories, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals 0 0 3 0 3.00
Impax Laboratories 1 5 4 0 2.30

Corbus Pharmaceuticals currently has a consensus target price of $26.67, indicating a potential upside of 267.82%. Impax Laboratories has a consensus target price of $22.20, indicating a potential upside of 21.31%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Impax Laboratories.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. The company was founded in 2009 and is based in Norwood, Massachusetts.

Impax Laboratories Company Profile

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements. The Impax Specialty Pharma segment engages in the development, sale, and distribution of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson's disease, and post-herpetic neuralgia, as well as other select specialty segments. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals USA, Inc. to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1995 and is headquartered in Hayward, California.

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply